Research programme: androgen receptor antagonists - Bristol-Myers Squibb
Alternative Names: BMS 501949; BMS 647176; BMS-779333Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Aza compounds; Heterocyclic bicyclo compounds; Hydantoins; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 21 Apr 2010 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
- 15 Jan 2008 Preclinical development is ongoing